Promising myeloma combo trial halted after just 4 patients

NCT ID NCT06163898

Terminated Disease control Sponsor: Celgene Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This very early study tested two drugs, alnuctamab and mezigdomide, together in people with multiple myeloma that had come back or stopped responding to treatment. The goal was to find a safe dose and see if the combination could shrink tumors. However, the trial was stopped early after enrolling only 4 participants, so we have very little information about how well it worked or what side effects occurred.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: alnuctamab and mezigdomide (with dexamethasone)
What this could lead to: If it had succeeded, this combination could have offered a new treatment option for people with multiple myeloma that stopped responding to other therapies.
What could go wrong: The trial was terminated early with only 4 participants, so we have very little data. It is too early to know if the combination is safe or effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Local Institution - 0018

New York, New York, 10065, United States
Local Institution - 0020

Jerusalem, 9112001, Israel
Local Institution - 0021

Petah Tikva, Central District, 4910021, Israel
Local Institution - 0030

Ramat Gan, Central District, 5262100, Israel
Local Institution - 0033

Birmingham, Alabama, 35294, United States
Local Institution - 0035

New Haven, Connecticut, 06511, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.